Nyxoah S.A.(NYXH)

Medical - Specialties · Mont-Saint-Guibert, WA

$1.43+0.02 (+1.42%)

Delayed quote: Oct 6, 2026, 1:58 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T18:04:24.378Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:04:24.378Z.

Quote observation: 2026-10-06T17:58:33.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -92,961,721.4042
Quote market capitalization: 143,104,125
Total debt · period ending 2026-06-30: 60,042,118.24
Cash · period ending 2026-06-30: 73,230,870.7

FMP input reference: 88249fb6bbade3b4ad802b4bad00c79a42ee89cc3a650020707e3f27628c9d48

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NYXH EBITDA Yield Metrics

EBITDA YIELD

N/A

NYXH Competitors' EBITDA Yield

NYXH

Nyxoah S.A.

Current

Market Cap

$143.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TARA

Protara Therapeutics, Inc.

vs NYXH

Market Cap

$142.76M

EBITDA Yield

N/A

TTM Avg

2.27%

3Y Avg

2.27%

5Y Avg

2.27%

STRO

Sutro Biopharma, Inc.

vs NYXH

Market Cap

$141.00M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs NYXH

Market Cap

$140.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMRX

Immuneering Corporation

vs NYXH

Market Cap

$140.31M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs NYXH

Market Cap

$146.26M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KRSA

Korsana Biosciences, Inc.

vs NYXH

Market Cap

$146.76M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACOG

Alpha Cognition Inc

vs NYXH

Market Cap

$138.93M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs NYXH

Market Cap

$147.73M

EBITDA Yield

N/A

TTM Avg

17.25%

3Y Avg

38.66%

5Y Avg

34.07%

AVXL

Anavex Life Sciences Corp.

vs NYXH

Market Cap

$148.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Nyxoah S.A. (NYXH)	$143.10M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$142.76M	N/A	2.27%	2.27%	2.27%
Sutro Biopharma, Inc. (STRO)vs ›	$141.00M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$140.52M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$140.31M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.26M	N/A	N/A	N/A	N/A
Korsana Biosciences, Inc. (KRSA)vs ›	$146.76M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$138.93M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$147.73M	N/A	17.25%	38.66%	34.07%
Anavex Life Sciences Corp. (AVXL)vs ›	$148.27M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

NYXH EBITDA Yield Metrics

NYXH Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics